Compare SDGR & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SDGR | MGTX |
|---|---|---|
| Founded | 1990 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 925.8M | 909.1M |
| IPO Year | 2020 | 2018 |
| Metric | SDGR | MGTX |
|---|---|---|
| Price | $12.15 | $9.36 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 7 |
| Target Price | $21.00 | ★ $24.57 |
| AVG Volume (30 Days) | ★ 1.3M | 619.5K |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 45.14 | 33.02 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $255,869,000.00 | $81,391,000.00 |
| Revenue This Year | $0.76 | $141.38 |
| Revenue Next Year | $4.60 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 23.29 | ★ 144.57 |
| 52 Week Low | $10.95 | $5.02 |
| 52 Week High | $27.63 | $11.85 |
| Indicator | SDGR | MGTX |
|---|---|---|
| Relative Strength Index (RSI) | 47.21 | 48.12 |
| Support Level | $11.18 | $7.13 |
| Resistance Level | $13.36 | $9.65 |
| Average True Range (ATR) | 0.65 | 0.48 |
| MACD | -0.06 | -0.07 |
| Stochastic Oscillator | 32.53 | 42.57 |
Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery. The software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have various stages of discovery and development. The majority of the company's revenue is derived from the Software segment. Geographically, it derives the maximum revenue from the United States.
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.